PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
EUDA vs. SLNO
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between EUDA and SLNO is -0.05. This indicates that the assets' prices tend to move in opposite directions. Negative correlation can be particularly beneficial for diversification and risk management, as one asset may offset the losses of the other during market fluctuations.


-0.50.00.51.0
Correlation: -0.0

Performance

EUDA vs. SLNO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in EUDA Health Holdings Limited (EUDA) and Soleno Therapeutics, Inc. (SLNO). The values are adjusted to include any dividend payments, if applicable.

0.00%200.00%400.00%600.00%800.00%NovemberDecember2025FebruaryMarchApril
-58.13%
745.17%
EUDA
SLNO

Key characteristics

Sharpe Ratio

EUDA:

1.26

SLNO:

1.21

Sortino Ratio

EUDA:

2.01

SLNO:

2.25

Omega Ratio

EUDA:

1.26

SLNO:

1.27

Calmar Ratio

EUDA:

1.48

SLNO:

0.90

Martin Ratio

EUDA:

5.40

SLNO:

6.35

Ulcer Index

EUDA:

22.82%

SLNO:

13.40%

Daily Std Dev

EUDA:

97.50%

SLNO:

70.54%

Max Drawdown

EUDA:

-95.02%

SLNO:

-99.86%

Current Drawdown

EUDA:

-59.88%

SLNO:

-89.34%

Fundamentals

Market Cap

EUDA:

$150.10M

SLNO:

$3.21B

EPS

EUDA:

-$0.62

SLNO:

-$4.38

PS Ratio

EUDA:

39.38

SLNO:

0.00

PB Ratio

EUDA:

0.00

SLNO:

13.09

Total Revenue (TTM)

EUDA:

$954.02K

SLNO:

$0.00

Gross Profit (TTM)

EUDA:

$221.04K

SLNO:

-$494.00K

EBITDA (TTM)

EUDA:

-$788.98K

SLNO:

-$151.05M

Returns By Period

In the year-to-date period, EUDA achieves a -9.72% return, which is significantly lower than SLNO's 55.68% return.


EUDA

YTD

-9.72%

1M

0.75%

6M

-3.12%

1Y

139.05%

5Y*

N/A

10Y*

N/A

SLNO

YTD

55.68%

1M

43.46%

6M

29.21%

1Y

88.37%

5Y*

9.40%

10Y*

-18.61%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

EUDA vs. SLNO — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EUDA
The Risk-Adjusted Performance Rank of EUDA is 8888
Overall Rank
The Sharpe Ratio Rank of EUDA is 9090
Sharpe Ratio Rank
The Sortino Ratio Rank of EUDA is 8787
Sortino Ratio Rank
The Omega Ratio Rank of EUDA is 8585
Omega Ratio Rank
The Calmar Ratio Rank of EUDA is 9191
Calmar Ratio Rank
The Martin Ratio Rank of EUDA is 8888
Martin Ratio Rank

SLNO
The Risk-Adjusted Performance Rank of SLNO is 8888
Overall Rank
The Sharpe Ratio Rank of SLNO is 8989
Sharpe Ratio Rank
The Sortino Ratio Rank of SLNO is 9090
Sortino Ratio Rank
The Omega Ratio Rank of SLNO is 8585
Omega Ratio Rank
The Calmar Ratio Rank of SLNO is 8484
Calmar Ratio Rank
The Martin Ratio Rank of SLNO is 9090
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

EUDA vs. SLNO - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for EUDA Health Holdings Limited (EUDA) and Soleno Therapeutics, Inc. (SLNO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for EUDA, currently valued at 1.26, compared to the broader market-2.00-1.000.001.002.003.00
EUDA: 1.26
SLNO: 1.21
The chart of Sortino ratio for EUDA, currently valued at 2.01, compared to the broader market-6.00-4.00-2.000.002.004.00
EUDA: 2.01
SLNO: 2.25
The chart of Omega ratio for EUDA, currently valued at 1.26, compared to the broader market0.501.001.502.00
EUDA: 1.26
SLNO: 1.27
The chart of Calmar ratio for EUDA, currently valued at 1.48, compared to the broader market0.001.002.003.004.00
EUDA: 1.48
SLNO: 2.93
The chart of Martin ratio for EUDA, currently valued at 5.40, compared to the broader market-5.000.005.0010.0015.0020.00
EUDA: 5.40
SLNO: 6.35

The current EUDA Sharpe Ratio is 1.26, which is comparable to the SLNO Sharpe Ratio of 1.21. The chart below compares the historical Sharpe Ratios of EUDA and SLNO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.00NovemberDecember2025FebruaryMarchApril
1.26
1.21
EUDA
SLNO

Dividends

EUDA vs. SLNO - Dividend Comparison

Neither EUDA nor SLNO has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

EUDA vs. SLNO - Drawdown Comparison

The maximum EUDA drawdown since its inception was -95.02%, roughly equal to the maximum SLNO drawdown of -99.86%. Use the drawdown chart below to compare losses from any high point for EUDA and SLNO. For additional features, visit the drawdowns tool.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%NovemberDecember2025FebruaryMarchApril
-59.88%
-5.01%
EUDA
SLNO

Volatility

EUDA vs. SLNO - Volatility Comparison

The current volatility for EUDA Health Holdings Limited (EUDA) is 18.09%, while Soleno Therapeutics, Inc. (SLNO) has a volatility of 40.14%. This indicates that EUDA experiences smaller price fluctuations and is considered to be less risky than SLNO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%NovemberDecember2025FebruaryMarchApril
18.09%
40.14%
EUDA
SLNO

Financials

EUDA vs. SLNO - Financials Comparison

This section allows you to compare key financial metrics between EUDA Health Holdings Limited and Soleno Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab